BioCentury | Jun 2, 2020
Finance

Hillhouse-backed $160M series B round to drive Genor’s first candidate to the market

...Programmed cell death 1 TNFα - tumor necrosis factor α Hongjiang Li, Staff Writer Biosimilar trastuzumab (GB221) Biosimilar infliximab...
BioCentury | Dec 7, 2019
Product Development

U.S. biosimilars glass--half full or half empty?

...the Remicade biosimilar from Celltrion and Pfizer, is 10-11% Carey said. In contrast, in Denmark biosimilar infliximab...
...Four of the five largest U.S. payers have policies in place to reimburse for a biosimilar infliximab...
...with the loss of rebates on a range of J&J’s products if they purchase a biosimilar infliximab...
BioCentury | Nov 26, 2019
Company News

Nov. 26 Company Quick Takes: Kyowa, Ardelyx expand partnership; plus ICER, Celltrion, Asahi-Veloxis and Merck

...Tumor necrosis factor alpha Elizabeth S. Eaton and Sandi Wong, Staff Writers Keytruda, pembrolizumab (MK-3475, lambrolizumab) Inflectra, Remsima, biosimilar infliximab-dyyb...
BioCentury | Jul 19, 2019
Company News

July 19 Company Quick Takes: First biosimilars of Avastin, Herceptin launched; plus Gilenya, Celltrion-Nan Fung and Celgene

...Tuxella, biosimilar rituximab-abbs (CT-P10) Gilenya, Imusera, fingolimod (FTY720, TDI-132) Herzuma, biosimilar trastuzumab-pkrb (CTP-6, CT-P6, CT-P26, CT-P06) Inflectra, Remsima, biosimilar infliximab-dyyb...
BioCentury | Jun 28, 2019
Company News

CHMP knocks Evenity for osteoporosis, backs Giapreza for hypotension

...Bruton’s tyrosine kinase; VEGFR-2 (KDR/Flk-1) - Vascular endothelial growth factor receptor 2 Sandi Wong, Staff Writer biosimilar infliximab...
BioCentury | Oct 12, 2018
Clinical News

FDA panel votes in favor of Celltrion's rituximab biosimilar

...letter from FDA citing GMP violations observed at Celltrion's manufacturing facility during production of Inflectra biosimilar infliximab-dyyb...
BioCentury | Oct 10, 2018
Company News

FDA panel votes in favor of Celltrion's rituximab biosimilar

...letter from FDA citing GMP violations observed at Celltrion's manufacturing facility during production of Inflectra biosimilar infliximab-dyyb...
BioCentury | Aug 31, 2018
Financial News

Biosimilars company Mabpharm sets sights on Hong Kong IPO

...and all have held managerial roles at Mabpharm subsidiaries Taizhou Mabtech Biotechnology Ltd. and Taizhou Mabtech...
BioCentury | Aug 22, 2018
Financial News

Biosimilars company Mabpharm sets sights on Hong Kong IPO

...and all have held managerial roles at Mabpharm subsidiaries Taizhou Mabtech Biotechnology Ltd. and Taizhou Mabtech...
BioCentury | Aug 3, 2018
Company News

Celltrion wins another biosimilar infliximab lawsuit

...KOSDAQ:068270), Incheon, South Korea Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Business: Autoimmune Mary Romeo Inflectra, Remsima, biosimilar infliximab-dyyb...
Items per page:
1 - 10 of 39